Product Code: 4637
Title:
Global Human Insulin Market, By Indication (Type I Diabetes, Type II Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Pre-Mixed, Inhaled, Ultra-Long Acting), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections), By Region, Forecast & Opportunities, 2025.
Global human insulin market was valued at USD 26.91 Billion in 2019 is expected to grow at a steady CAGR of 8.01% during the forecast period. Growing geriatric population, increasing diabetic patients, rising prevalence of obesity, and increasing demand for human insulin analogs are contributing to the surging demand for human insulin market, globally. Now a days, diabetes is not only restricted to geriatric population, but it is also common among youth. Also, the technological advancements have eradicated human physical activities leading to obesity and diabetes disorders which is directly influencing the growth of the market. Cost effectiveness, reimbursement prices and strict regulatory requirements for approval of insulin can be considered as a major restraining factor for the market as everyone suffering from diabetes might not be able to afford insulin.
The global human insulin market is segmented on the basis of indication, brand, route of administration, type, onset type, products, and region. Based on indication, market can be bifurcated into type I diabetes and type II diabetes. Type I diabetes is likely to hold the largest market share until 2025 as, human insulin is the most important treatment method for the people suffering from type I diabetes. Based on brand, Lantus segment held the dominant market which is one of the major selling products of Sanofi S.A. As of 2019, subcutaneous segment was the leading segment on the basis of route of administration. This is the most common and preferred route of administration as the insulin is absorbed more quickly. Based on regional analysis, North America dominated the human insulin market in 2019 due to large pool of population suffering from diabetes and presence of leading companies in countries like US and Canada.
Leading players in the global human insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk A/S, Torrent Pharmaceuticals, Inc., Eli Lilly and Company, A-S Medication Solutions, RemedyRepack Inc., Sedico Co., Pharmaceutical Company, Sanofi S.A., Gan & Lee Pharmaceuticals, BioGenomics Ltd., Pfizer Inc., PerkinElmer, Merck & Co., Inc, Biocon Limited, Wockhardt Ltd., Ypsomed AG, Becton Dickinson and Company, B. Braun Melsungen AG, Baxter International Inc., among others.
Years considered for this report:
- Historical Years: 2015-2018
- Forecast Period: 2021-2025
Objective of the Study:
- To analyze and forecast the market size of global human insulin market.
- To classify and forecast global human insulin market based on indication, brand, route of administration, type, onset type, products and region.
- To identify drivers and challenges for global human insulin market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global human insulin market.
- To conduct pricing analysis for global human insulin market.
- To identify and analyze the profile of leading players operating in global human insulin market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of hospitals/clinics across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the hospitals/clinics which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals/clinics and presence of all major players across the globe.
TechSci Research calculated the market size of global human insulin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:
- Hospitals/clinics, research institutes and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to human insulin
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as hospitals/clinics, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, global human insulin market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Type I Diabetes
Type II Diabetes
Lantus
Humulin R
Novolin R
Humulin N
Exubera
Afrezza
Novolin N
- Market, By Route of Administration:
Subcutaneous
Nasal
Intravenous
Transdermal
Oral
Others
Basal
Bolus
Pre-mixed
Biosimilar
Traditional
Rapid acting
Short-acting
Intermediate acting
Long acting
Ultra-long acting
Pre-mixed
Inhaled
Insulin Pens
Insulin Pumps
Infusion System
Injection
North America
- United States
- Mexico
- Canada
Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Russia
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Singapore
South America
- Brazil
- Argentina
- Colombia
Middle east & Africa
- Saudi Arabia
- South Africa
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global human insulin market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on Global Human Insulin Market
4. Executive Summary
5. Voice of Customer
6. Global Human Insulin Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Indication (Type I Diabetes, Type II Diabetes)
- 6.2.2. By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N)
- 6.2.3. By Route of administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others)
- 6.2.4. By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional)
- 6.2.5. By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
- 6.2.6. By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection)
- 6.2.7. By Company (2019)
- 6.2.8. By Region
- 6.3. Market Attractiveness Index
7. North America Human Insulin Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Indication
- 7.2.2. By Brand
- 7.2.3. By Route of Administration
- 7.2.4. By Type
- 7.2.5. By Onset Time
- 7.2.6. By Products
- 7.2.7. By Country
- 7.3. Market Attractiveness Index
- 7.4. North America: Country Analysis
- 7.4.1. United States Human Insulin Market Outlook
- 7.4.1.1. Market Size & Forecast
- 7.4.1.2. Market Share & Forecast
- 7.4.1.2.1. By Indication
- 7.4.1.2.2. By Brand
- 7.4.1.2.3. By Route of Administration
- 7.4.1.2.4. By Type
- 7.4.1.2.5. By Onset Time
- 7.4.1.2.6. By Products
- 7.4.2. Canada Human Insulin Market Outlook
- 7.4.2.1. Market Size & Forecast
- 7.4.2.2. Market Share & Forecast
- 7.4.2.2.1. By Indication
- 7.4.2.2.2. By Brand
- 7.4.2.2.3. By Route of Administration
- 7.4.2.2.4. By Type
- 7.4.2.2.5. By Onset Time
- 7.4.2.2.6. By Products
- 7.4.3. Mexico Human Insulin Market Outlook
- 7.4.3.1. Market Size & Forecast
- 7.4.3.2. Market Share & Forecast
- 7.4.3.2.1. By Indication
- 7.4.3.2.2. By Brand
- 7.4.3.2.3. By Route of Administration
- 7.4.3.2.4. By Type
- 7.4.3.2.5. By Onset Time
- 7.4.3.2.6. By Products
8. Europe Human Insulin Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Indication
- 8.2.2. By Brand
- 8.2.3. By Route of Administration
- 8.2.4. By Type
- 8.2.5. By Onset Time
- 8.2.6. By Products
- 8.2.7. By Country
- 8.3. Market Attractiveness Index
- 8.4. Europe: Country Analysis
- 8.4.1. Germany Human Insulin Market Outlook
- 8.4.1.1. Market Size & Forecast
- 8.4.1.2. Market Share & Forecast
- 8.4.1.2.1. By Indication
- 8.4.1.2.2. By Brand
- 8.4.1.2.3. By Route of Administration
- 8.4.1.2.4. By Type
- 8.4.1.2.5. By Onset Time
- 8.4.1.2.6. By Products
- 8.4.2. United Kingdom Human Insulin Market Outlook
- 8.4.2.1. Market Size & Forecast
- 8.4.2.2. Market Share & Forecast
- 8.4.2.2.1. By Indication
- 8.4.2.2.2. By Brand
- 8.4.2.2.3. By Route of Administration
- 8.4.2.2.4. By Type
- 8.4.2.2.5. By Onset Time
- 8.4.2.2.6. By Products
- 8.4.3. France Human Insulin Market Outlook
- 8.4.3.1. Market Size & Forecast
- 8.4.3.2. Market Share & Forecast
- 8.4.3.2.1. By Indication
- 8.4.3.2.2. By Brand
- 8.4.3.2.3. By Route of Administration
- 8.4.3.2.4. By Type
- 8.4.3.2.5. By Onset Time
- 8.4.3.2.6. By Products
- 8.4.4. Italy Human Insulin Market Outlook
- 8.4.4.1. Market Size & Forecast
- 8.4.4.2. Market Share & Forecast
- 8.4.4.2.1. By Indication
- 8.4.4.2.2. By Brand
- 8.4.4.2.3. By Route of Administration
- 8.4.4.2.4. By Type
- 8.4.4.2.5. By Onset Time
- 8.4.4.2.6. By Products
- 8.4.5. Spain Human Insulin Market Outlook
- 8.4.5.1. Market Size & Forecast
- 8.4.5.2. Market Share & Forecast
- 8.4.5.2.1. By Indication
- 8.4.5.2.2. By Brand
- 8.4.5.2.3. By Route of Administration
- 8.4.5.2.4. By Type
- 8.4.5.2.5. By Onset Time
- 8.4.5.2.6. By Products
- 8.4.6. Russia Human Insulin Market Outlook
- 8.4.6.1. Market Size & Forecast
- 8.4.6.2. Market Share & Forecast
- 8.4.6.2.1. By Indication
- 8.4.6.2.2. By Brand
- 8.4.6.2.3. By Route of Administration
- 8.4.6.2.4. By Type
- 8.4.6.2.5. By Onset Time
- 8.4.6.2.6. By Products
9. Asia-Pacific Human Insulin Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Indication
- 9.2.2. By Brand
- 9.2.3. By Route of Administration
- 9.2.4. By Type
- 9.2.5. By Onset Time
- 9.2.6. By Products
- 9.2.7. By Country
- 9.3. Market Attractiveness Index
- 9.4. Asia-Pacific: Country Analysis
- 9.4.1. China Human Insulin Market Outlook
- 9.4.1.1. Market Size & Forecast
- 9.4.1.2. Market Share & Forecast
- 9.4.1.2.1. By Indication
- 9.4.1.2.2. By Brand
- 9.4.1.2.3. By Route of Administration
- 9.4.1.2.4. By Type
- 9.4.1.2.5. By Onset Time
- 9.4.1.2.6. By Products
- 9.4.2. India Human Insulin Market Outlook
- 9.4.2.1. Market Size & Forecast
- 9.4.2.2. Market Share & Forecast
- 9.4.2.2.1. By Indication
- 9.4.2.2.2. By Brand
- 9.4.2.2.3. By Route of Administration
- 9.4.2.2.4. By Type
- 9.4.2.2.5. By Onset Time
- 9.4.2.2.6. By Products
- 9.4.3. Japan Human Insulin Market Outlook
- 9.4.3.1. Market Size & Forecast
- 9.4.3.2. Market Share & Forecast
- 9.4.3.2.1. By Indication
- 9.4.3.2.2. By Brand
- 9.4.3.2.3. By Route of Administration
- 9.4.3.2.4. By Type
- 9.4.3.2.5. By Onset Time
- 9.4.3.2.6. By Products
- 9.4.4. South Korea Human Insulin Market Outlook
- 9.4.4.1. Market Size & Forecast
- 9.4.4.2. Market Share & Forecast
- 9.4.4.2.1. By Indication
- 9.4.4.2.2. By Brand
- 9.4.4.2.3. By Route of Administration
- 9.4.4.2.4. By Type
- 9.4.4.2.5. By Onset Time
- 9.4.4.2.6. By Products
- 9.4.5. Australia Human Insulin Market Outlook
- 9.4.5.1. Market Size & Forecast
- 9.4.5.2. Market Share & Forecast
- 9.4.5.2.1. By Indication
- 9.4.5.2.2. By Brand
- 9.4.5.2.3. By Route of Administration
- 9.4.5.2.4. By Type
- 9.4.5.2.5. By Onset Time
- 9.4.5.2.6. By Products
- 9.4.6. Singapore Human Insulin Market Outlook
- 9.4.6.1. Market Size & Forecast
- 9.4.6.2. Market Share & Forecast
- 9.4.6.2.1. By Indication
- 9.4.6.2.2. By Brand
- 9.4.6.2.3. By Route of Administration
- 9.4.6.2.4. By Type
- 9.4.6.2.5. By Onset Time
- 9.4.6.2.6. By Products
10. South America Human Insulin Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value & Volume
- 10.2. Market Share & Forecast
- 10.2.1. By Indication
- 10.2.2. By Brand
- 10.2.3. By Route of Administration
- 10.2.4. By Type
- 10.2.5. By Onset Time
- 10.2.6. By Products
- 10.2.7. By Country
- 10.3. Market Attractiveness Index
- 10.4. South America: Country Analysis
- 10.4.1. Brazil Human Insulin Market Outlook
- 10.4.1.1. Market Size & Forecast
- 10.4.1.2. Market Share & Forecast
- 10.4.1.2.1. By Indication
- 10.4.1.2.2. By Brand
- 10.4.1.2.3. By Route of Administration
- 10.4.1.2.4. By Type
- 10.4.1.2.5. By Onset Time
- 10.4.1.2.6. By Products
- 10.4.2. Argentina Human Insulin Market Outlook
- 10.4.2.1. Market Size & Forecast
- 10.4.2.2. Market Share & Forecast
- 10.4.2.2.1. By Indication
- 10.4.2.2.2. By Brand
- 10.4.2.2.3. By Route of Administration
- 10.4.2.2.4. By Type
- 10.4.2.2.5. By Onset Time
- 10.4.2.2.6. By Products
- 10.4.3. Colombia Human Insulin Market Outlook
- 10.4.3.1. Market Size & Forecast
- 10.4.3.2. Market Share & Forecast
- 10.4.3.2.1. By Indication
- 10.4.3.2.2. By Brand
- 10.4.3.2.3. By Route of Administration
- 10.4.3.2.4. By Type
- 10.4.3.2.5. By Onset Time
- 10.4.3.2.6. By Products
11. Middle East and Africa Human Insulin Market Outlook
- 11.1. Market Size & Forecast
- 11.1.1. By Value & Volume
- 11.2. Market Share & Forecast
- 11.2.1. By Indication
- 11.2.2. By Brand
- 11.2.3. By Route of Administration
- 11.2.4. By Type
- 11.2.5. By Onset Time
- 11.2.6. By Products
- 11.2.7. By Country
- 11.3. Market Attractiveness Index
- 11.4. MEA: Country Analysis
- 11.4.1. Saudi Arabia Human Insulin Market Outlook
- 11.4.1.1. Market Size & Forecast
- 11.4.1.2. Market Share & Forecast
- 11.4.1.2.1. By Indication
- 11.4.1.2.2. By Brand
- 11.4.1.2.3. By Route of Administration
- 11.4.1.2.4. By Type
- 11.4.1.2.5. By Onset Time
- 11.4.1.2.6. By Products
- 11.4.2. South Africa Human Insulin Market Outlook
- 11.4.2.1. Market Size & Forecast
- 11.4.2.2. Market Share & Forecast
- 11.4.2.2.1. By Indication
- 11.4.2.2.2. By Brand
- 11.4.2.2.3. By Route of Administration
- 11.4.2.2.4. By Type
- 11.4.2.2.5. By Onset Time
- 11.4.2.2.6. By Products
- 11.4.3. UAE Human Insulin Market Outlook
- 11.4.3.1. Market Size & Forecast
- 11.4.3.2. Market Share & Forecast
- 11.4.3.2.1. By Indication
- 11.4.3.2.2. By Brand
- 11.4.3.2.3. By Route of Administration
- 11.4.3.2.4. By Type
- 11.4.3.2.5. By Onset Time
- 11.4.3.2.6. By Products
12. Market Dynamics
- 12.1. Drivers
- 12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
- 14.1. Competition Outlook
- 14.2. Players Profiled (Leading Companies)
- 14.2.1. Novo Nordisk A/S
- 14.2.2. Sanofi S.A.
- 14.2.3. Eli Lilly and Company
- 14.2.4. Biocon Limited
- 14.2.5. Wockhardt Ltd
- 14.2.6. Nektar Therapeutics
- 14.2.7. Mannkind Corporation
- 14.2.8. A-S Medication Solutions
- 14.2.9. Remedyrepack Inc.
- 14.2.10. Torrent Pharmaceuticals
- 14.2.11. Sedico Co.
- 14.2.12. Gan & Lee Pharmaceuticals
- 14.2.13. BioGenomics Ltd
- 14.2.14. Ypsomed AG
- 14.2.15. Becton, Dickinson and Company
- 14.2.16. B. Braun Melsungen AG
- 14.2.17. Baxter International Inc.,
- 14.2.18. Merck & Co., Inc
- 14.2.19. PerkinElmer
- 14.2.20. Pfizer Inc.
15. Strategic Recommendations
16. About Us & Disclaimer
比較リスト
